Shell Asset Management Co. Sells 54,965 Shares of Gilead Sciences, Inc. $GILD

Shell Asset Management Co. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.5% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 31,624 shares of the biopharmaceutical company’s stock after selling 54,965 shares during the period. Shell Asset Management Co.’s holdings in Gilead Sciences were worth $3,510,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after acquiring an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC grew its stake in Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the period. Norges Bank bought a new position in Gilead Sciences in the 2nd quarter valued at $2,150,268,000. Invesco Ltd. increased its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the last quarter. Finally, Amundi raised its stake in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after purchasing an additional 1,614,355 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the insider directly owned 103,221 shares of the company’s stock, valued at $12,831,402.51. This trade represents a 2.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This trade represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Needham & Company LLC raised their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a research report on Wednesday. Twenty-three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $152.50.

Gilead Sciences Stock Up 2.1%

GILD opened at $154.98 on Friday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a market cap of $192.28 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 1.24 and a beta of 0.36. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a 50 day moving average of $130.27 and a 200 day moving average of $122.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 46.68%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.